Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2026-08-28)
EUR 3.35-1.06%

Evotec SE
UMushroom community rating:

star star star star star
4.29 7 votes No rating yet
NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-44.2%1Y
-83.8%3Y
-92.2%5Y

Performance

57.5%1Y
69.2%3Y
61.3%5Y

Volatility

Market cap

689 M

Market cap (USD)

Daily traded volume (Shares)

424,031

Daily traded volume (Shares)

1 day high/low

8.73 / 8.45

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.29

7 votes
Performance:
starstarstarstarstar
4.29
Innovation:
starstarstarstarstar
4.29
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.86
Meret Jaggi
Switzerland, 30 May 2022
star star star star star
Oliver Moon
Switzerland, 30 May 2022
star star star star star
German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.
Atanas WI Atanasov
Switzerland, 30 May 2022
star star star star star

EQUITIES OF THE SAME SECTOR

Globus Medical Inc
Globus Medical Inc Globus Medical Inc Valor: 18329123
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.52%USD 82.97
Tenet Healthcare Corp
Tenet Healthcare Corp Tenet Healthcare Corp Valor: 19722583
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.35%USD 266.80
Douglas AG
Douglas AG Douglas AG Valor: 133507391
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.88%EUR 8.13
Emeis
Emeis Emeis Valor: 132546338
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.47%EUR 12.72
PACS Group Inc
PACS Group Inc PACS Group Inc Valor: 133777092
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.37%USD 42.75
Agenus Inc
Agenus Inc Agenus Inc Valor: 134326284
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.92%USD 7.66
Laurus Labs Ltd.
Laurus Labs Ltd. Laurus Labs Ltd. Valor: 56464789
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.80%INR 1,935.30
Tempus AI Inc
Tempus AI Inc Tempus AI Inc Valor: 135855934
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-9.41%USD 64.04
NATCO Pharma Limited
NATCO Pharma Limited NATCO Pharma Limited Valor: 30461955
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.57%INR 853.35
Teladoc Health Inc
Teladoc Health Inc Teladoc Health Inc Valor: 28438140
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.20%USD 6.50